News >

Hurvitz Highlights Emerging Agents for Heavily Pretreated HER2+ Breast Cancer

Brandon Scalea
Published: Thursday, Mar 21, 2019

Sara A. Hurvitz, MD

Sara A. Hurvitz, MD
While there are well-established standard therapies for first- and second-line settings in patients with HER2-positive metastatic breast cancer, Sara A. Hurvitz, MD, said that a number of novel agents and combinations are poised to shape later lines of treatment.

, Hurvitz discussed recent updates in the paradigm and promising therapeutic strategies on the horizon for patients with HER2-positive metastatic breast cancer.

OncLive: What is the current treatment landscape for patients with HER2-positive metastatic breast cancer?

Hurvitz: It's a really exciting time to be treating patients with HER2-positive metastatic breast cancer because of the many therapeutic options we now have available. The standard of care is to treat patients in the frontline setting with trastuzumab, pertuzumab (Perjeta), and a taxane. The taxane is given for 4 to 6 cycles, and then the patients go on to maintenance trastuzumab and pertuzumab. That is the gold standard based on findings from the CLEOPATRA study, which showed a significant improvement in overall survival (OS) with that triplet strategy. The second gold standard is second-line ado-trastuzumab emtansine (T-DM1; Kadcyla), which is an antibody-drug conjugate (ADC) that targets HER2. This is the gold standard based on data from the EMILIA study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x